For most of its first decade as a public company, Zoetis was the kind of business that made investors feel smart. It sold medicines to pets and livestock, a market that grows steadily because people do not stop loving their animals during recessions. Revenue climbed from $6.7 billion in 2020 to $9.5 billion by the end of 2025, and margins widened every few years. Then, in 2026, a competitor started discounting aggressively in the dermatology drugs that Zoetis had long dominated, veterinary visits softened, and the stock fell nearly in half. Today the shares trade at $71.05, down roughly 50% from their peak. The question the filings raise is whether the price now reflects a broken business or a temporarily bruised one.
What the numbers say
The filed record shows a company that has grown revenue every year for five years and kept more than a quarter of each sales dollar as profit. The current stock price implies a multiple, meaning the price paid per dollar of annual profit, that sits at the lowest point in at least a decade, our data show. Management guided in August 2026 for a modest revenue decline this year, not a collapse. Those two readings, a historically low valuation and a business still generating substantial profit, represent a tension the filings alone cannot resolve; the outcome depends on whether the dermatology headwinds prove temporary or structural.
What the price is saying
A price-to-earnings multiple is simply the price tag per dollar of annual profit. A company earning $1 per share and trading at $15 carries a multiple of 15. Over the past decade, investors have typically paid about 32 times Zoetis’s annual earnings to own the stock, our data show. Today they are paying about 11 times. That is not a discount. That is the market saying something has permanently changed, and demanding proof before it pays anything close to the old rate.
The price-to-sales ratio, which compares the stock price to each dollar of revenue rather than profit, tells the same story. The decade median is roughly 8.6 times sales. The stock now trades at 3.2 times, our data show, a level that has never appeared in this company’s modern history. For a business still posting nearly 28% net margins, meaning it keeps about 28 cents of profit from every dollar it collects, that gap between the filed math and the market’s mood is striking.
What the filings actually show
If the filed numbers hold and the dermatology headwinds prove temporary, the gap between current sentiment and reported fundamentals would be wide; if the headwinds prove structural, the current multiple may be less anomalous than it appears.
In its second-quarter 2026 results announced August 6, Zoetis reported total revenue of $2.5 billion for the quarter, flat year-over-year. The U.S. companion animal segment, which sells drugs like Apoquel for itchy dogs, fell 11% as a new competitor began discounting heavily. That is a real problem. But the international segment grew meaningfully, and global livestock sales rose at a double-digit rate in the same quarter. The business is not falling apart uniformly. One room is on fire; the rest of the house is standing.
For the full year, management guided for revenue in a range that would represent a decline of roughly one to three percent from 2025’s level. Adjusted earnings per share are guided at $6.15 to $6.25. At the midpoint of that range, the stock trades at about 11 times this year’s expected earnings, a valuation more commonly seen in slow-growth industrial companies than in pharmaceutical businesses with gross margins above 72%. A gross margin is what remains of each sales dollar after the cost of making the product; at that level, Zoetis spends less than 28 cents making what it sells for a dollar, leaving the rest to cover overhead and generate profit.
The dermatology problem, in plain terms
Zoetis built a commanding position in veterinary dermatology, the drugs that treat skin conditions in dogs and cats. Apoquel, its flagship pill for itch, held roughly 87% of the U.S. in-clinic dermatology market as recently as mid-2026, according to analysis published by TIKR. That share fell meaningfully year-over-year in Q2 2026 as rivals entered with lower prices. Think of it like a pharmacy that held the only allergy pill in town for years, then watched a generic arrive and start handing out coupons. Zoetis’s CEO Kristin Peck confirmed in mid-September remarks covered by MarketBeat that the company will not cut list prices, instead using targeted rebates to hold share. That is a defensible strategy, but it costs margin in the short run.
The backstory matters here. Zoetis was spun out of Pfizer in 2013 specifically because animal health was seen as a steadier, less regulated business than human drugs. For most of its public life, that thesis held. The dermatology franchise was the crown jewel, a near-monopoly in a market where pet owners spend freely because a dog scratching itself raw is not something most families tolerate. The arrival of competition does not end that market. It ends the monopoly pricing within it.
What is still working
The livestock business is growing at a double-digit rate, and diagnostics, the machines and tests that veterinary clinics use to analyze blood and tissue, grew strongly in Q2 2026. Zoetis has been quietly building this diagnostics arm for years, acquiring a teleradiology platform called VitalRADS in July 2026 and agreeing to buy Neogen’s animal genomics business for $160 million in March 2026. These are not transformational deals, but they suggest a management team still investing in the future rather than retreating.
Free cash flow, the actual dollars left after running the business and maintaining its assets, remained substantial through the first half of 2026, according to reporting by Biggo Finance. The company returned hundreds of millions to shareholders through buybacks in the most recent quarter, against a multi-billion remaining repurchase authorization. It also raised its quarterly dividend earlier this year. These capital allocation decisions, buybacks, a dividend increase, and bolt-on acquisitions, are consistent with management’s stated confidence in the business trajectory, as described in the August 2026 earnings release.
The gap the market has to resolve
Analysts tracked by MarketBeat carry a consensus valuation estimate near $102 as of the date of this article; that figure reflects their own assumptions about earnings recovery and multiple expansion, which are detailed in their individual reports. SimplyWall St notes that normalized earnings estimates for 2027 sit meaningfully above current-year guidance. If, for example, 2027 adjusted EPS were to recover to the midpoint of the analyst consensus range and the P/E multiple were to revert to half its decade median, roughly 16 times, the arithmetic would produce a price in the range of approximately $99 to $101. Whether either condition is met depends on the dermatology trajectory and broader pet-care demand, neither of which the current filings resolve.
The honest uncertainty is this: we do not know how much further dermatology share falls, or whether the softer pet-care market reflects a lasting shift in how much Americans spend on their animals. Those are real questions the filings cannot yet answer. What the filings can answer is that the business earned $6.02 per share in 2025, guided for $6.15 to $6.25 in 2026, and is still generating cash at a rate that funds buybacks, dividends, and acquisitions simultaneously. The gap between the filed earnings trajectory and the current valuation multiple is, by historical measure, unusually wide. Whether that gap closes through price recovery, earnings deterioration, or a prolonged period of both is a question the available filings leave open.
Reading the numbers
- P/E of 11.3 vs. decade median of 32.2. The P/E, or price-to-earnings multiple, is the price per dollar of annual profit. Zoetis’s decade median of 32.2 means investors historically paid $32.20 for every $1 of earnings. Today they pay $11.30. A household analogy: imagine a rental property that historically sold for 32 times its annual rent income now listed at 11 times. Either the rent is about to collapse, or the price is unusually low. Based on the BullScope valuation database covering fiscal years 2015–2025, this reading sits at the lowest point in the company’s available public history. Whether that reflects a genuine structural break or a temporary dislocation is the central question the filings have not yet answered.
- Revenue guidance of $9.12B to $9.32B for 2026. This figure comes from Zoetis’s August 6, 2026 earnings release. It represents a decline of roughly 2% at the midpoint from 2025’s $9.5 billion. To feel the scale: the stock costs $71 against a business still generating roughly $9.2 billion in annual revenue. The market is paying a fraction of the revenue multiple that historically characterised this company.
- Adjusted EPS guidance of $6.15 to $6.25 for 2026. EPS, or earnings per share, is the portion of annual profit attributed to each share outstanding. At $6.20 midpoint and a $71 stock price, a holder of one share is paying roughly 11.5 years of current earnings for the right to own that share indefinitely. The decade median implied a buyer would pay 32 years of earnings. The gap between 11.5 and 32 is where the story lives.
- Gross margin of 72.9% in Q2 2026. The gross margin is what remains of each sales dollar after paying to make the product, before overhead, marketing, and taxes. At 72.9%, Zoetis keeps nearly 73 cents of every dollar it collects before those costs. A bakery keeping 73 cents of every dollar of bread sales before paying rent or staff would be considered extraordinarily efficient. This figure comes from the 10-Q for the quarter ended June 30, 2026.
- U.S. companion animal sales down 11% in Q2 2026, livestock up 11%. Both figures come from the August 6, 2026 earnings release, and together they illustrate why the headline revenue number understates the complexity. One segment is contracting under competitive pressure; another is growing at a healthy clip. A household budget analogy: imagine a family whose grocery spending fell 11% because a cheaper store opened nearby, but whose home-repair spending rose 11% because they finally fixed the roof. The total bill is roughly flat, but the story inside it is very different.
For the standing yardsticks on Zoetis: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Zoetis.
Sources
- Zoetis Q2 2026 earnings release, August 6, 2026
- Zoetis 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Zoetis 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Zoetis 10-K, fiscal year ended December 31, 2024 (SEC EDGAR)
- TIKR: Zoetis cut its 2026 guide in Q2 earnings
- MarketBeat: Zoetis stands by guidance, September 18, 2026
- MarketBeat: Zoetis analyst consensus and valuation estimates
- SimplyWall St: Zoetis future earnings estimates
- Zoetis press release: VitalRADS acquisition, July 2026
- Tracxn: Zoetis acquisitions history
- Biggo Finance: Zoetis capital allocation and cash flow, August 2026
- Zoetis dividend declaration, Q1 2026
